Effectiveness of tislelizumab when combined with etoposide and carboplatin in patients with SMARCA4-deficient undifferentiated thoracic tumor: a case report

BACKGROUND: SMARCA4-deficient undifferentiated thoracic tumor (SMARCA4-UT) is a rare malignant condition with high invasiveness and poor prognosis. Presently, no clear guidelines are available for the treatment of SMARCA4-UT. The median overall survival was only four to seven months. Several patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Pan, Xiong, Fu, Lin, Yong, Liang, Peiqiang, Tang, Chunlan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175004/
https://www.ncbi.nlm.nih.gov/pubmed/37180644
http://dx.doi.org/10.21037/tcr-22-1679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175004/
https://www.ncbi.nlm.nih.gov/pubmed/37180644
http://dx.doi.org/10.21037/tcr-22-1679

Ejemplares similares